Reducing the prohibitive costs of protein production for therapeutic development

PhylloTech公司是通过消除蛋白质和抗体的生产 用于昂贵的制造、纯化和下游处理步骤。本公司已 开发了一种逆向方法，通过工程在植物中生产蛋白质和抗体 烟草叶结构，称为腺体分泌毛状体，以制造，纯化和递送 将蛋白质直接靶向到活植物的叶表面，以方便和经济地收获。的 然后，蛋白质可以被包装并直接销售给最终用户或发送到填充/完成操作。 价值主张是可以在低成本下以低成本产生大量的纯化蛋白质， 可再生，环保的方式。我们把这个表达系统叫做OnLeafEX， 有了这个系统，PhylloTech可以消除阻碍未来发展的高昂成本 基于蛋白质的治疗剂的产生。我们正在追求细胞因子的研究用途只 市场细分作为一个直接的机会，因为他们的限制性高成本，高 需求和海外采购。该项目的具体目标是： 具体目标1 -设计编码25种细胞因子的基因序列， 密码子优化的N.烟草，并放入专有的植物载体中。 特异性目标2 -稳定的植物转化体将用以下标准方案产生： 农杆菌介导的植物转化。 具体目标3 -然后将经消毒的植物转移到无菌土壤中并在 我们的室内植物生长设施和植物产生的细胞因子将被收获。 具体目标4 -收获的植物产生的细胞因子将进行内部验证， 分析了 具体目标5 -植物产生的细胞因子将被外部验证活性，并进一步 为商业化而开发。 这项工作的目的是使用在植物中发现的一种新的制造技术， 通过降低成本，显著增加患者对治疗的可及性， OnLeafEX，该公司处于最大限度地利用这一商机的理想位置。 与细胞因子和其他研究工具相关的研究和开发成本可能会降低。 大大减少，可能允许更快地采用治疗方法。该技术将 还可以降低合作伙伴公司的COGS，从而提供更大的利润， 财务稳定的组织，可以通过节省病人，从而降低 治疗药物的零售价格。

PhylloTech, Inc. is redefining the production of proteins and antibodies by eliminating the need for expensive manufacturing, purification, and downstream processing steps. The company has developed a contrarian method to produce proteins and antibodies in plants by engineering tobacco leaf structures, called glandular secreting trichomes, to manufacture, purify, and deliver target proteins directly to leaf surfaces of living plants for easy and economical harvests. The proteins can then be packaged and sold directly to the end user or sent to fill/finish operations. The value proposition is that high amounts of purified proteins can be generated at low cost in a renewable, environmentally friendly manner. We call this expression system OnLeafEX, and with this system, PhylloTech can eliminate the prohibitive costs that are forestalling the future generation of protein-based therapeutics. We are pursuing the cytokine research use only market segment as an immediate opportunity because of their restrictively high costs, high demand, and overseas sourcing. The specific aims of the project are: Specific Aim 1 – Genetic sequences encoding twenty-five cytokines will be designed and codon-optimized for N. tabacum, and placed into proprietary plant vectors. Specific Aim 2 - Stable plant transformants will be generated with standard protocols of Agrobacterium-mediated plant transformation. Specific Aim 3 - Propagated plants will then be transferred to sterile soil and grown in our indoor plant growth facility, and plant-made cytokines will be harvested. Specific Aim 4 – Harvested plant-made cytokines will be internally validated and analyzed. Specific Aim 5 – Plant-made cytokines will be externally validated for activity and further developed for commercialization. The aim of this work is to use a novel manufacturing technology discovered in plants to dramatically increase patient’s accessibility to therapeutics by lowering their costs, and with OnLeafEX, the company is in an ideal position to maximize this business opportunity. Research and development costs associated with cytokines and other research tools could be drastically reduced, potentially allowing for faster adoption of therapeutics. The technology will also lower the COGS for partner companies, providing larger margins and ultimately more financial stability to organizations that can pass the savings onto patients, resulting in lower retail prices for therapeutics.